Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19484140 | 0.90 | NPC1 (0.32) | TRPV1NPC1RAB9ACFTRNAMPT | |
| SCHEMBL17482991 | 0.89 | CFTR (0.33) | TRPV1NPC1RAB9ACFTRNAMPT | |
| SCHEMBL19483599 | 0.89 | NPC1 (0.32) | TRPV1NPC1RAB9ACFTRNAMPT | |
| SCHEMBL19484134 | 0.84 | NPC1 (0.33) | TRPV1NPC1RAB9ANAMPT | |
| SCHEMBL19484143 | 0.81 | NPC1 (0.32) | TRPV1NPC1RAB9A | |
| SCHEMBL17483070 | 0.81 | NPC1 (0.34) | TRPV1NPC1RAB9ACFTRNAMPT | |
| SCHEMBL19484149 | 0.80 | KMT2A (0.45) | NPC1RAB9A | |
| SCHEMBL19484152 | 0.80 | NPC1 (0.31) | TRPV1NPC1RAB9ANAMPT | |
| SCHEMBL19483585 | 0.79 | TRPV1 (0.33) | TRPV1NPC1RAB9ACFTRNAMPT | |
| SCHEMBL19484136 | 0.78 | MEN1 (0.36) | TRPV1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | OPRM1, TRPA1, L3MBTL3 | TRPV1 52/4885NPC1 3696/4885RAB9A 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.